contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


amendment-of-the-nomination-committees-proposal-for-ablivas-annual-general-meeting-in-2023

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Abliva

The notice for Abliva’s Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee's proposal for the election of Board members was presented...

<div class="mfn-body"><p>The notice for Abliva’s Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee's proposal for the election of Board members was presented in the press release. The Nomination Committee has now been informed that Dr. Edwin Moses is no longer available for re-election for personal reasons. David Laskow-Pooley has accepted re-election to the Board in addition to David Bejker, Jan Törnell, Denise Goode and Roger Franklin. The Nomination Committee proposes that David Laskow-Pooley is re-elected as Chair of the Board. The Nomination Committee also proposes a revised fee for the chairman of the board to be paid out at SEK 435,000 (400,000). Further, the Nomination Committee proposes a bonus payment in cash to David Laskow-Pooley of SEK 937,500. David Laskow-Pooley is required to use the full amount of the Bonus, net after income tax to acquire Abliva shares on the stock market. The company will pay the social security costs. The shares acquired for the Bonus will be locked in for a period of three (3) years after the acquisition.</p><p>“We are pleased that David Laskow-Pooley will continue in his position as Chairman of the Board of Abliva and look forward to his leadership as the company continues the Phase 2 FALCON study evaluating the efficacy of KL1333 in patients with primary mitochondrial disease,” said Ingrid Teigland Akay, chair of the Nomination Committee.</p><p>Information about existing Board members can be found on the company's website<a rel="noopener" href="http://www.abliva.com/"> www.abliva.com</a></p></div><div class="mfn-footer mfn-d318f2261daa"><p><strong class="mfn-heading-1">For more information, please contact:</strong></p><hr><p>Catharina Johansson, Deputy CEO, CFO&nbsp;&amp; VP Investor Relations<br>+46 (0)46-275 62 21, <a rel="noopener" href="mailto:ir@abliva.com">ir@abliva.com</a></p><p><strong>Abliva AB (publ)</strong><br>Medicon Village, SE-223 81 Lund, Sweden<br>Tel: +46 (0)46 275 62 20 (switchboard)<br><a rel="noopener" href="mailto:info@abliva.com">info@abliva.com</a>,&nbsp;<a rel="noopener" href="http://www.abliva.com">www.abliva.com</a></p><p>Subscribe to our news:&nbsp;<a rel="noopener" href="https://abliva.com/posts/news-subscription/">https://abliva.com/posts/news-subscription/</a><br>Follow&nbsp;us&nbsp;on LinkedIn:&nbsp;<a rel="noopener" href="https://www.linkedin.com/company/abliva">https://www.linkedin.com/company/abliva</a><br>Subscribe&nbsp;to&nbsp;our YouTube&nbsp;channel:&nbsp;<a rel="noopener" href="https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg">https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg</a></p></div><div class="mfn-footer mfn-72682e636cb1"><p><strong class="mfn-heading-1">Abliva – Delivering mitochondrial health</strong></p><hr><p>Abliva discovers and develops medicines for the treatment of mitochondrial diseases. These rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is in clinical trials. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/45afcd42-e707-468f-b417-e2e363065da9/amendment-of-the-nomination-committees-proposal-for-ablivas-annual-general-meeting-in-2023.pdf" class="mfn-generated mfn-primary">Amendment of the Nomination Committee's proposal for Abliva’s Annual General Meeting in 2023</a></p></div>

Amendment of the Nomination Committee's proposal for Abliva’s Annual General Meeting in 2023